First United Bank & Trust Sells 763 Shares of Johnson & Johnson (NYSE:JNJ)

First United Bank & Trust lowered its position in Johnson & Johnson (NYSE:JNJ) by 4.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,015 shares of the company’s stock after selling 763 shares during the period. First United Bank & Trust’s holdings in Johnson & Johnson were worth $2,433,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of JNJ. Heartwood Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 112.0% in the first quarter. Heartwood Wealth Advisors LLC now owns 8,757 shares of the company’s stock worth $1,385,000 after acquiring an additional 4,627 shares during the period. Duncan Williams Asset Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth about $512,000. Cullen Investment Group LTD. boosted its stake in shares of Johnson & Johnson by 2.7% in the first quarter. Cullen Investment Group LTD. now owns 68,585 shares of the company’s stock worth $10,818,000 after acquiring an additional 1,793 shares during the period. CWM LLC boosted its stake in shares of Johnson & Johnson by 8.3% in the first quarter. CWM LLC now owns 386,640 shares of the company’s stock worth $61,163,000 after acquiring an additional 29,778 shares during the period. Finally, Davis Capital Management boosted its stake in shares of Johnson & Johnson by 6.2% in the first quarter. Davis Capital Management now owns 9,144 shares of the company’s stock worth $1,443,000 after acquiring an additional 531 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Morgan Stanley boosted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. TD Securities decreased their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Trading Up 1.6 %

JNJ opened at $164.14 on Wednesday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock’s fifty day moving average is $162.70 and its two-hundred day moving average is $154.52. The company has a market capitalization of $395.02 billion, a P/E ratio of 10.23, a PEG ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period last year, the business posted $2.80 EPS. The business’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.